Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA.
Scott Department of Urology, Baylor College of Medicine, Houston, TX, USA; Center for Reproductive Medicine, Baylor College of Medicine, Houston, TX, USA.
Sex Med. 2016 Mar;4(1):e28-33. doi: 10.1016/j.esxm.2015.09.001.
Male orgasmic disorder is common, with few treatment options. Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction.
To determine whether cabergoline increases the potential for orgasm in men with orgasmic disorder.
A retrospective chart review of men treated in a single andrology clinic for delayed orgasm or anorgasmia in a pilot study using cabergoline 0.5 mg twice weekly was performed. Duration of treatment and response were noted. Medical records were examined for other factors including history of prostatectomy and concomitant androgen supplementation.
Subjective improvement in orgasmic function resulting from cabergoline treatment.
Of 131 men treated with cabergoline for orgasmic disorder, 87 (66.4%) reported subjective improvement in orgasm and 44 (33.6%) reported no change in orgasm. Duration of therapy (P = .03) and concomitant testosterone therapy (P = .02) were associated with a significant positive response to cabergoline treatment. No differences were found between injectable and non-injectable testosterone formulations (P = .90), and neither age (P = .90) nor prior prostatectomy (P = .41) influenced the outcome of cabergoline treatment. Serum testosterone levels before (P = .26) and after (P = .81) treatment were not significantly different in responders vs non-responders.
Cabergoline is a potentially effective and easy-to-administer treatment for male orgasmic disorder, the efficacy of which appears to be independent of patient age or orgasmic disorder etiology. Prospective randomized trials are needed to determine the true role of cabergoline in the treatment of this disorder.
男性性高潮障碍很常见，治疗选择有限。卡麦角林是一种多巴胺激动剂，可在中枢发挥作用，使血清催乳素正常化，从而改善性功能障碍。
确定卡麦角林是否能提高性高潮障碍男性的性高潮能力。
对在一个单一的男科诊所接受卡麦角林（每周两次，每次 0.5 毫克）治疗的男性进行了一项回顾性图表研究，这些男性患有延迟性高潮或不射精症。记录治疗持续时间和反应。检查了病历中其他因素，包括前列腺切除术史和同时使用雄激素补充剂。
卡麦角林治疗后性高潮功能的主观改善。
在 131 名接受卡麦角林治疗性高潮障碍的男性中，87 名（66.4%）报告性高潮功能主观改善，44 名（33.6%）报告性高潮无变化。治疗持续时间（P=.03）和同时使用睾酮治疗（P=.02）与卡麦角林治疗的显著阳性反应相关。注射和非注射睾酮制剂之间没有差异（P=.90），年龄（P=.90）和前列腺切除术史（P=.41）均不影响卡麦角林治疗的结果。在有反应者和无反应者中，治疗前后的血清睾酮水平均无显著差异（P=.26 和 P=.81）。
卡麦角林是一种治疗男性性高潮障碍的潜在有效且易于管理的治疗方法，其疗效似乎与患者年龄或性高潮障碍病因无关。需要前瞻性随机试验来确定卡麦角林在治疗这种疾病中的真正作用。
